Skip to main content
Opens in new window
NHS Wales
NHS 111 Wales
Skip Navigation
Accessibility
Contact us
Cymraeg
Cymraeg
All...
Search
All Wales Therapeutics and Toxicology Centre
Search
Cymraeg
Cymraeg
Menu
Home
Accessing medicines
Show Submenu For Accessing medicines
Access to medicines in Wales
Medicine recommendations
Make a submission
Medicines optimisation and safety
Show Submenu For Medicines optimisation and safety
Medicines optimisation guidance, resources and data
Yellow Card Centre Wales
Welsh National Poisons Unit
Work in progress
News, meetings and events
Show Submenu For News, meetings and events
News
Meetings
Events
About us
Show Submenu For About us
Who we are
What we do
Our committees
Who we work with
Our research
Our reports and strategies
Sustainability
Contact us
More
×
WHSSC Specialised Services Policy: CP118 Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene
Welsh Health Specialised Services Committee (WHSSC)
WHSSC Specialised Services Policy CP55: Drug treatment for lysosomal storage disorders
WHSSC Specialised Services Policy CP100: Elosulfase alfa (Vimizim) for the management of MPS Type IVA
WHSSC Specialised Services Policy CP98: Eculizumab for Atypical Haemolytic Uraemic Syndrome (aHUS)
NHS Wales
NHS 111 Wales
Accessibility
Contact us
All...
Search
Listen
Home
›
Links
›
WHSSC
WHSSC
23/02/2023
WHSSC Specialised Services Policy: CP118 Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene
27/03/2020
Welsh Health Specialised Services Committee (WHSSC)
27/02/2020
WHSSC Specialised Services Policy CP55: Drug treatment for lysosomal storage disorders
27/02/2020
WHSSC Specialised Services Policy CP100: Elosulfase alfa (Vimizim) for the management of MPS Type IVA
27/02/2020
WHSSC Specialised Services Policy CP98: Eculizumab for Atypical Haemolytic Uraemic Syndrome (aHUS)
Follow AWTTC:
